Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor

KR Gans, W Galbraith, RJ Roman, SB Haber, JS Kerr, WK Schmidt, C Smith, WE Hewes and NR Ackerman

Medical Products Department, E. I. du Pont de Nemours & Co., Inc., Wilmington, Delaware.

DuP 697 (5-bromo-2[4-fluorophenyl]-3-[4-methylsulfonylphenyl]- thiophene) is a potent inhibitor of paw swelling in nonestablished and established adjuvant arthritis in rats (ED50 = 0.03 and 0.18 mg/kg/day, respectively). DuP 697 had no effect on phenylquinone writhing in rats (ED50 greater than 100 mg/kg), but was analgetic against inflammation- related pain in the Randall-Selitto assay (ED30 = 3.5 mg/kg) and was a very potent antipyretic agent (ED50 = 0.05 mg/kg). The drug was not ulcerogenic in rats at single doses up to 400 mg/kg. DuP 697 (5 mg/kg i.v.) did not alter renal blood flow or the renal vascular response to angiotensin II in furosemide-pretreated, volume-depleted rats. In contrast, indomethacin (5 mg/kg i.v.) decreased renal blood flow and potentiated the renal vascular response to angiotensin II in these animals. DuP 697 was a moderate inhibitor of bull seminal vesicle prostaglandin (PG) synthesis (IC50 = 2.4 X 10(-5) M) and a potent inhibitor of rat brain PG synthesis (IC50 = 4.5 X 10(-6) M) but was ineffective against rat kidney PG synthesis (IC50 7.5 X 10(-5) M). These differential effects of DuP 697 on PG synthesis by various tissues may account for its high potency as an anti-inflammatory and antipyretic agent and its minimal toxicity profile.

Volume 254, Issue 1, pp. 180-187, 07/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				R. Rajakariar, M. M. Yaqoob, and D. W. Gilroy COX-2 in Inflammation and Resolution Mol. Interv., August 1, 2006; 6(4): 199 - 207. [Abstract] [Full Text] [PDF]

				A. A. Romanovsky Vioxx, Celebrex, Bextra....Do we have a new target for anti-inflammatory and antipyretic therapy? Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2005; 288(5): R1098 - R1099. [Full Text] [PDF]

				R. R. Harris, L. Black, S. Surapaneni, T. Kolasa, S. Majest, M. T. Namovic, G. Grayson, V. Komater, D. Wilcox, L. King, et al. ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 904 - 912. [Abstract] [Full Text] [PDF]

				K. Tsuboi, A. Iwane, S. Nakazawa, Y. Sugimoto, and A. Ichikawa Role of Prostaglandin H2 Synthase 2 in Murine Parturition: Study on Ovariectomy-Induced Parturition in Prostaglandin F Receptor-Deficient Mice Biol Reprod, July 1, 2003; 69(1): 195 - 201. [Abstract] [Full Text] [PDF]

				J. Reese, X. Zhao, W.-G. Ma, N. Brown, T. J. Maziasz, and S. K. Dey Comparative Analysis of Pharmacologic and/or Genetic Disruption of Cyclooxygenase-1 and Cyclooxygenase-2 Function in Female Reproduction in Mice Endocrinology, July 1, 2001; 142(7): 3198 - 3206. [Abstract] [Full Text] [PDF]

				A. Rouleau, H. Stark, W. Schunack, and J.-C. Schwartz Anti-Inflammatory and Antinociceptive Properties of BP 2-94, a Histamine H3-Receptor Agonist Prodrug J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 219 - 225. [Abstract] [Full Text]

				Y. Takahashi, C. Roman, S. Chemtob, M. M. Tse, E. Lin, M. A. Heymann, and R. I. Clyman Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2000; 278(6): R1496 - R1505. [Abstract] [Full Text] [PDF]

				A. S. Kalgutkar, B. C. Crews, S. W. Rowlinson, A. B. Marnett, K. R. Kozak, R. P. Remmel, and L. J. Marnett Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors PNAS, January 18, 2000; 97(2): 925 - 930. [Abstract] [Full Text] [PDF]

				D. L. DeWitt Cox-2-Selective Inhibitors: The New Super Aspirins Mol. Pharmacol., April 1, 1999; 55(4): 625 - 631. [Full Text]

				R. I. Clyman, P. Hardy, N. Waleh, Y. Q. Chen, F. Mauray, J.-C. Fouron, and S. Chemtob Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1999; 276(3): R913 - R921. [Abstract] [Full Text] [PDF]

				L. Cullen, L. Kelly, S. O. Connor, and D. J. Fitzgerald Selective Cyclooxygenase-2 Inhibition by Nimesulide in Man J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 578 - 582. [Abstract] [Full Text]

				M. M. Taketo Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I) J Natl Cancer Inst, October 21, 1998; 90(20): 1529 - 1536. [Abstract] [PDF]

				G. M. Greig, D. A. Francis, J.-P. Falgueyret, M. Ouellet, M. D. Percival, P. Roy, C. Bayly, J. A. Mancini, and G. P. O'Neill The Interaction of Arginine 106 of Human Prostaglandin G/H Synthase-2 with Inhibitors Is Not a Universal Component of Inhibition Mediated by Nonsteroidal Anti-inflammatory Drugs Mol. Pharmacol., November 1, 1997; 52(5): 829 - 838. [Abstract] [Full Text]

				E. Wong, C. Bayly, H. L. Waterman, D. Riendeau, and J. A. Mancini Conversion of Prostaglandin G/H Synthase-1 into an Enzyme Sensitive to PGHS-2-selective Inhibitors by a Double His513 right-arrow Arg and Ile523 right-arrow Val Mutation J. Biol. Chem., April 4, 1997; 272(14): 9280 - 9286. [Abstract] [Full Text] [PDF]

				J. A. Mancini, P. J. Vickers, G. P. O'Neill, C. Boily, J.-P. Falgueyret, and D. Riendeau Altered Sensitivity of Aspirin-Acetylated Prostaglandin G/H Synthase-2 to Inhibition by Nonsteroidal Anti-Inflammatory Drugs Mol. Pharmacol., January 1, 1997; 51(1): 52 - 60. [Abstract] [Full Text]

				P. Harding, D. H. Sigmon, M. E. Alfie, P. L. Huang, M. C. Fishman, W. H. Beierwaltes, and O. A. Carretero Cyclooxygenase-2 Mediates Increased Renal Renin Content Induced by Low-Sodium Diet Hypertension, January 1, 1997; 29(1): 297 - 302. [Abstract] [Full Text] [PDF]